Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | SD-101 |
Synonyms | |
Therapy Description |
SD-101 is an oligonucleotide which interacts with Toll-Like Receptor 9 (TLR9) and activates memory T helper cells 1 (Th1) (PMID: 30154193, PMID: 31921384). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
SD-101 | SD101|SD 101 | TLR9 Agonist 9 | SD-101 is an oligonucleotide which interacts with Toll-Like Receptor 9 (TLR9) and activates memory T helper cells 1 (Th1) (PMID: 30154193, PMID: 31921384). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02521870 | Phase I | Pembrolizumab SD-101 | A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma | Terminated | USA | NZL | DEU | AUS | 0 |
NCT02266147 | Phase Ib/II | SD-101 | Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma | Terminated | USA | 0 |
NCT01745354 | Phase I | SD-101 | Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT) | Terminated | USA | 0 |